Butantan biomedical institute in Brazil's Sao Paulo state is in talks to sell a locally manufactured COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac Biotech (Nasdaq:SVA) to other countries in South America and Africa, Reuters news agency reported on Thursday.
The Brazilian federal government has not ordered more of Sinovac's COVID-19 vaccine doses, but Butantan has contracts to supply the vaccine directly to Brazilian states.
Currently, Butantan is producing Sinovac's CoronaVac shot using inputs imported from China. It aims to complete a factory for 100% local production by early next year.
Earlier this month, Butantan completed its contract to deliver 100 million doses of CoronaVac to Brazil's Health Ministry, without another deal in place.
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Sanofi in talks to sell Opella stake
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
Anixa Biosciences plans Phase 2 breast cancer vaccine study
MedImmune's FluMist nasal spray influenza vaccine receives US FDA approval
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine